Listed

Editas Medicine, Inc.

EDITNasdaqCIK 1650664HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$11.9m, Q2 FY2026
Operating income−$18.6m, Q2 FY2026
Net income−$18.2m, Q2 FY2026
Editas Medicine, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m5.3Revenue, Q3 FY2023, three months to 2023-09-30$5.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-04, accession 0001650664-24-000121.Report this figure60.0Revenue, Q4 FY2023, three months to 2023-12-31$60.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-05, accession 0001650664-25-000022. Derived: 12-month figure less the 9-month figure.Report this figure1.1Revenue, Q1 FY2024, three months to 2024-03-31$1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-12, accession 0001650664-25-000073.Report this figure0.5Revenue, Q2 FY2024, three months to 2024-06-30$513.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-12, accession 0001650664-25-000125.Report this figure0.1Revenue, Q3 FY2024, three months to 2024-09-30$61.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure30.6Revenue, Q4 FY2024, three months to 2024-12-31$30.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-09, accession 0001650664-26-000017. Derived: 12-month figure less the 9-month figure.Report this figure4.7Revenue, Q1 FY2025, three months to 2025-03-31$4.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure3.6Revenue, Q2 FY2025, three months to 2025-06-30$3.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure7.5Revenue, Q3 FY2025, three months to 2025-09-30$7.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure24.7Revenue, Q4 FY2025, three months to 2025-12-31$24.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-09, accession 0001650664-26-000017. Derived: 12-month figure less the 9-month figure.Report this figure2.8Revenue, Q1 FY2026, three months to 2026-03-31$2.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure11.9Revenue, Q2 FY2026, three months to 2026-06-30$11.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure
Research and development$m40.5Research and development, Q3 FY2023, three months to 2023-09-30$40.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-04, accession 0001650664-24-000121.Report this figure69.6Research and development, Q4 FY2023, three months to 2023-12-31$69.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-05, accession 0001650664-25-000022. Derived: 12-month figure less the 9-month figure.Report this figure48.8Research and development, Q1 FY2024, three months to 2024-03-31$48.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-12, accession 0001650664-25-000073.Report this figure54.2Research and development, Q2 FY2024, three months to 2024-06-30$54.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-12, accession 0001650664-25-000125.Report this figure47.6Research and development, Q3 FY2024, three months to 2024-09-30$47.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure48.6Research and development, Q4 FY2024, three months to 2024-12-31$48.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-09, accession 0001650664-26-000017. Derived: 12-month figure less the 9-month figure.Report this figure26.6Research and development, Q1 FY2025, three months to 2025-03-31$26.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure16.2Research and development, Q2 FY2025, three months to 2025-06-30$16.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure19.8Research and development, Q3 FY2025, three months to 2025-09-30$19.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure27.4Research and development, Q4 FY2025, three months to 2025-12-31$27.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-09, accession 0001650664-26-000017. Derived: 12-month figure less the 9-month figure.Report this figure17.6Research and development, Q1 FY2026, three months to 2026-03-31$17.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure20.2Research and development, Q2 FY2026, three months to 2026-06-30$20.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure
Operating income$m(50.2)Operating income, Q3 FY2023, three months to 2023-09-30−$50.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-04, accession 0001650664-24-000121.Report this figure(24.0)Operating income, Q4 FY2023, three months to 2023-12-31−$24.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-05, accession 0001650664-25-000022. Derived: 12-month figure less the 9-month figure.Report this figure(67.0)Operating income, Q1 FY2024, three months to 2024-03-31−$67.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0001650664-25-000073.Report this figure(71.9)Operating income, Q2 FY2024, three months to 2024-06-30−$71.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-12, accession 0001650664-25-000125.Report this figure(65.7)Operating income, Q3 FY2024, three months to 2024-09-30−$65.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure(46.6)Operating income, Q4 FY2024, three months to 2024-12-31−$46.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001650664-26-000017. Derived: 12-month figure less the 9-month figure.Report this figure(76.2)Operating income, Q1 FY2025, three months to 2025-03-31−$76.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure(51.5)Operating income, Q2 FY2025, three months to 2025-06-30−$51.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure(24.5)Operating income, Q3 FY2025, three months to 2025-09-30−$24.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure(7.8)Operating income, Q4 FY2025, three months to 2025-12-31−$7.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001650664-26-000017. Derived: 12-month figure less the 9-month figure.Report this figure(25.0)Operating income, Q1 FY2026, three months to 2026-03-31−$25.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure(18.6)Operating income, Q2 FY2026, three months to 2026-06-30−$18.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reported2.1Interest expense, Q1 FY2025, three months to 2025-03-31$2.1m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure0.0Interest expense, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-05, accession 0001650664-26-000083. Derived: 6-month figure less the 3-month figure.Report this figurenot reportednot reported5.0Interest expense, Q1 FY2026, three months to 2026-03-31$5.0m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure0.0Interest expense, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-05, accession 0001650664-26-000083. Derived: 6-month figure less the 3-month figure.Report this figure
Net income$m(45.0)Net income, Q3 FY2023, three months to 2023-09-30−$45.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-04, accession 0001650664-24-000121.Report this figure(18.9)Net income, Q4 FY2023, three months to 2023-12-31−$18.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-05, accession 0001650664-25-000022. Derived: 12-month figure less the 9-month figure.Report this figure(62.0)Net income, Q1 FY2024, three months to 2024-03-31−$62.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure(67.6)Net income, Q2 FY2024, three months to 2024-06-30−$67.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure(62.1)Net income, Q3 FY2024, three months to 2024-09-30−$62.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure(45.4)Net income, Q4 FY2024, three months to 2024-12-31−$45.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001650664-26-000017. Derived: 12-month figure less the 9-month figure.Report this figure(76.1)Net income, Q1 FY2025, three months to 2025-03-31−$76.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure(53.2)Net income, Q2 FY2025, three months to 2025-06-30−$53.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure(25.1)Net income, Q3 FY2025, three months to 2025-09-30−$25.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure(5.6)Net income, Q4 FY2025, three months to 2025-12-31−$5.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001650664-26-000017. Derived: 12-month figure less the 9-month figure.Report this figure(25.0)Net income, Q1 FY2026, three months to 2026-03-31−$25.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure(18.2)Net income, Q2 FY2026, three months to 2026-06-30−$18.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure
Diluted EPS$ per share(0.55)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-04, accession 0001650664-24-000121.Report this figurenot reported(0.76)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.76 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0001650664-25-000073.Report this figure(0.82)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-12, accession 0001650664-25-000125.Report this figure(0.75)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figurenot reported(0.92)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure(0.63)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.63 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure(0.28)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figurenot reported(0.26)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure(0.15)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure
Basic EPS$ per share(0.55)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-04, accession 0001650664-24-000121.Report this figurenot reported(0.76)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.76 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0001650664-25-000073.Report this figure(0.82)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.82 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-12, accession 0001650664-25-000125.Report this figure(0.75)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.75 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figurenot reported(0.92)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.92 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure(0.63)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.63 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure(0.28)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figurenot reported(0.26)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure(0.15)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure

Balance sheet

Cash and equivalents$181.8m, Q2 FY2026
Long-term debt$48.2m, Q2 FY2026
Shareholders' equity$105.3m, Q2 FY2026
Editas Medicine, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m82.5Cash and equivalents, Q3 FY2023, at 2023-09-30$82.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-04, accession 0001650664-24-000121.Report this figure124Cash and equivalents, FY2023, at 2023-12-31$123.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-05, accession 0001650664-25-000022.Report this figure69.2Cash and equivalents, Q1 FY2024, at 2024-03-31$69.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0001650664-25-000073.Report this figure64.4Cash and equivalents, Q2 FY2024, at 2024-06-30$64.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-12, accession 0001650664-25-000125.Report this figure95.8Cash and equivalents, Q3 FY2024, at 2024-09-30$95.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure132Cash and equivalents, FY2024, at 2024-12-31$131.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-09, accession 0001650664-26-000017.Report this figure139Cash and equivalents, Q1 FY2025, at 2025-03-31$138.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure139Cash and equivalents, Q2 FY2025, at 2025-06-30$138.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure166Cash and equivalents, Q3 FY2025, at 2025-09-30$165.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure147Cash and equivalents, FY2025, at 2025-12-31$146.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure124Cash and equivalents, Q1 FY2026, at 2026-03-31$123.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure182Cash and equivalents, Q2 FY2026, at 2026-06-30$181.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure
Current assets$m359Current assets, Q3 FY2023, at 2023-09-30$358.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-03, accession 0001650664-23-000017.Report this figure341Current assets, FY2023, at 2023-12-31$340.8m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-05, accession 0001650664-25-000022.Report this figure306Current assets, Q1 FY2024, at 2024-03-31$305.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-08, accession 0001650664-24-000037.Report this figure286Current assets, Q2 FY2024, at 2024-06-30$286.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-07, accession 0001650664-24-000097.Report this figure271Current assets, Q3 FY2024, at 2024-09-30$271.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-04, accession 0001650664-24-000121.Report this figure289Current assets, FY2024, at 2024-12-31$289.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-09, accession 0001650664-26-000017.Report this figure225Current assets, Q1 FY2025, at 2025-03-31$224.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0001650664-25-000073.Report this figure183Current assets, Q2 FY2025, at 2025-06-30$182.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-12, accession 0001650664-25-000125.Report this figure177Current assets, Q3 FY2025, at 2025-09-30$176.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure164Current assets, FY2025, at 2025-12-31$163.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure128Current assets, Q1 FY2026, at 2026-03-31$128.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure218Current assets, Q2 FY2026, at 2026-06-30$218.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure
Total assets$m505Total assets, Q3 FY2023, at 2023-09-30$504.6m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-03, accession 0001650664-23-000017.Report this figure499Total assets, FY2023, at 2023-12-31$499.2m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-05, accession 0001650664-25-000022.Report this figure440Total assets, Q1 FY2024, at 2024-03-31$440.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-08, accession 0001650664-24-000037.Report this figure385Total assets, Q2 FY2024, at 2024-06-30$384.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-07, accession 0001650664-24-000097.Report this figure328Total assets, Q3 FY2024, at 2024-09-30$327.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-04, accession 0001650664-24-000121.Report this figure342Total assets, FY2024, at 2024-12-31$341.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-09, accession 0001650664-26-000017.Report this figure264Total assets, Q1 FY2025, at 2025-03-31$263.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0001650664-25-000073.Report this figure211Total assets, Q2 FY2025, at 2025-06-30$210.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-12, accession 0001650664-25-000125.Report this figure202Total assets, Q3 FY2025, at 2025-09-30$201.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure187Total assets, FY2025, at 2025-12-31$186.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure149Total assets, Q1 FY2026, at 2026-03-31$149.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure237Total assets, Q2 FY2026, at 2026-06-30$237.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure
Current liabilities$m58.6Current liabilities, Q3 FY2023, at 2023-09-30$58.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-03, accession 0001650664-23-000017.Report this figure63.2Current liabilities, FY2023, at 2023-12-31$63.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-05, accession 0001650664-25-000022.Report this figure66.5Current liabilities, Q1 FY2024, at 2024-03-31$66.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-08, accession 0001650664-24-000037.Report this figure74.3Current liabilities, Q2 FY2024, at 2024-06-30$74.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-07, accession 0001650664-24-000097.Report this figure72.4Current liabilities, Q3 FY2024, at 2024-09-30$72.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-04, accession 0001650664-24-000121.Report this figure77.2Current liabilities, FY2024, at 2024-12-31$77.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-09, accession 0001650664-26-000017.Report this figure73.1Current liabilities, Q1 FY2025, at 2025-03-31$73.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0001650664-25-000073.Report this figure65.9Current liabilities, Q2 FY2025, at 2025-06-30$65.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-12, accession 0001650664-25-000125.Report this figure61.8Current liabilities, Q3 FY2025, at 2025-09-30$61.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure46.2Current liabilities, FY2025, at 2025-12-31$46.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure39.8Current liabilities, Q1 FY2026, at 2026-03-31$39.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure68.4Current liabilities, Q2 FY2026, at 2026-06-30$68.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure
Total liabilities$m144Total liabilities, Q3 FY2023, at 2023-09-30$144.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-03, accession 0001650664-23-000017.Report this figure150Total liabilities, FY2023, at 2023-12-31$150.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-05, accession 0001650664-25-000022.Report this figure146Total liabilities, Q1 FY2024, at 2024-03-31$145.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-08, accession 0001650664-24-000037.Report this figure153Total liabilities, Q2 FY2024, at 2024-06-30$152.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-07, accession 0001650664-24-000097.Report this figure152Total liabilities, Q3 FY2024, at 2024-09-30$151.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-04, accession 0001650664-24-000121.Report this figure207Total liabilities, FY2024, at 2024-12-31$207.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-09, accession 0001650664-26-000017.Report this figure201Total liabilities, Q1 FY2025, at 2025-03-31$201.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-12, accession 0001650664-25-000073.Report this figure191Total liabilities, Q2 FY2025, at 2025-06-30$191.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-12, accession 0001650664-25-000125.Report this figure188Total liabilities, Q3 FY2025, at 2025-09-30$188.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure159Total liabilities, FY2025, at 2025-12-31$159.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure145Total liabilities, Q1 FY2026, at 2026-03-31$144.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure132Total liabilities, Q2 FY2026, at 2026-06-30$132.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure
Long-term debt$mnot reported0.0Long-term debt, FY2023, at 2023-12-31$0. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2025-03-05, accession 0001650664-25-000022.Report this figurenot reportednot reportednot reported52.4Long-term debt, FY2024, at 2024-12-31$52.4m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2026-03-09, accession 0001650664-26-000017.Report this figure49.6Long-term debt, Q1 FY2025, at 2025-03-31$49.6m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-05-12, accession 0001650664-25-000073.Report this figure51.7Long-term debt, Q2 FY2025, at 2025-06-30$51.7m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-08-12, accession 0001650664-25-000125.Report this figure54.1Long-term debt, Q3 FY2025, at 2025-09-30$54.1m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure53.6Long-term debt, FY2025, at 2025-12-31$53.6m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure47.2Long-term debt, Q1 FY2026, at 2026-03-31$47.2m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure48.2Long-term debt, Q2 FY2026, at 2026-06-30$48.2m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure
Current portion of debt$mnot reported0.0Current portion of debt, FY2023, at 2023-12-31$0. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2025-03-05, accession 0001650664-25-000022.Report this figurenot reportednot reportednot reported5.0Current portion of debt, FY2024, at 2024-12-31$5.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2026-03-09, accession 0001650664-26-000017.Report this figure5.0Current portion of debt, Q1 FY2025, at 2025-03-31$5.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2025-05-12, accession 0001650664-25-000073.Report this figure5.0Current portion of debt, Q2 FY2025, at 2025-06-30$5.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2025-08-12, accession 0001650664-25-000125.Report this figure5.0Current portion of debt, Q3 FY2025, at 2025-09-30$5.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure5.0Current portion of debt, FY2025, at 2025-12-31$5.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure7.5Current portion of debt, Q1 FY2026, at 2026-03-31$7.5m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure7.5Current portion of debt, Q2 FY2026, at 2026-06-30$7.5m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure
Shareholders' equity$m360Shareholders' equity, Q3 FY2023, at 2023-09-30$360.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-04, accession 0001650664-24-000121.Report this figure349Shareholders' equity, FY2023, at 2023-12-31$349.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-09, accession 0001650664-26-000017.Report this figure294Shareholders' equity, Q1 FY2024, at 2024-03-31$294.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure232Shareholders' equity, Q2 FY2024, at 2024-06-30$232.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure176Shareholders' equity, Q3 FY2024, at 2024-09-30$175.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure134Shareholders' equity, FY2024, at 2024-12-31$134.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure62.4Shareholders' equity, Q1 FY2025, at 2025-03-31$62.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure19.2Shareholders' equity, Q2 FY2025, at 2025-06-30$19.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure13.5Shareholders' equity, Q3 FY2025, at 2025-09-30$13.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure27.3Shareholders' equity, FY2025, at 2025-12-31$27.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure4.4Shareholders' equity, Q1 FY2026, at 2026-03-31$4.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure105Shareholders' equity, Q2 FY2026, at 2026-06-30$105.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure

Cash flow

Operating cash flow−$29.6m, Q2 FY2026
Capital expenditure$106.0k, Q2 FY2026
Editas Medicine, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(35.5)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$35.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-04, accession 0001650664-24-000121. Derived: 9-month figure less the 6-month figure.Report this figure(22.2)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$22.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-05, accession 0001650664-25-000022. Derived: 12-month figure less the 9-month figure.Report this figure(49.9)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$49.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0001650664-25-000073.Report this figure(57.1)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$57.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-12, accession 0001650664-25-000125. Derived: 6-month figure less the 3-month figure.Report this figure(52.6)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$52.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001650664-25-000156. Derived: 9-month figure less the 6-month figure.Report this figure(50.8)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$50.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-09, accession 0001650664-26-000017. Derived: 12-month figure less the 9-month figure.Report this figure(47.8)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$47.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure(50.2)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$50.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001650664-26-000083. Derived: 6-month figure less the 3-month figure.Report this figure(30.8)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$30.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001650664-25-000156. Derived: 9-month figure less the 6-month figure.Report this figure(36.4)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$36.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-09, accession 0001650664-26-000017. Derived: 12-month figure less the 9-month figure.Report this figure(23.1)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$23.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure(29.6)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$29.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001650664-26-000083. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.2Capital expenditure, Q3 FY2023, three months to 2023-09-30$239.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-04, accession 0001650664-24-000121. Derived: 9-month figure less the 6-month figure.Report this figure1.3Capital expenditure, Q4 FY2023, three months to 2023-12-31$1.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-05, accession 0001650664-25-000022. Derived: 12-month figure less the 9-month figure.Report this figure1.9Capital expenditure, Q1 FY2024, three months to 2024-03-31$1.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-12, accession 0001650664-25-000073.Report this figure3.5Capital expenditure, Q2 FY2024, three months to 2024-06-30$3.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-12, accession 0001650664-25-000125. Derived: 6-month figure less the 3-month figure.Report this figure2.9Capital expenditure, Q3 FY2024, three months to 2024-09-30$2.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001650664-25-000156. Derived: 9-month figure less the 6-month figure.Report this figure0.5Capital expenditure, Q4 FY2024, three months to 2024-12-31$540.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-09, accession 0001650664-26-000017. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2025, three months to 2025-03-31$114.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001650664-26-000083. Derived: 6-month figure less the 3-month figure.Report this figure0.4Capital expenditure, Q3 FY2025, three months to 2025-09-30$433.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001650664-25-000156. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2025, three months to 2025-12-31$60.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-09, accession 0001650664-26-000017. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2026, three months to 2026-03-31$92.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure0.1Capital expenditure, Q2 FY2026, three months to 2026-06-30$106.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001650664-26-000083. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)119.29m, Q2 FY2026
Editas Medicine, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares68.7Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3068,736,125 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-03, accession 0001650664-23-000017.Report this figure68.9Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3168,924,180 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-08, accession 0001650664-24-000037.Report this figure71.4Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3071,376,678 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-07, accession 0001650664-24-000097.Report this figure81.6Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3081,648,250 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-04, accession 0001650664-24-000121.Report this figure81.9Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3181,938,839 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0001650664-25-000073.Report this figure82.3Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3082,310,368 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-12, accession 0001650664-25-000125.Report this figure82.5Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3082,485,199 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure83.1Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3183,055,066 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure84.4Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3084,412,200 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure90.1Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3090,090,397 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001650664-25-000156.Report this figure97.9Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3197,879,343 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-05, accession 0001650664-26-000045.Report this figure119Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30119,294,615 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure

Shares outstanding: 153.58mShares outstanding, period not labelled, at 2026-07-31153,580,035 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-05, accession 0001650664-26-000083.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 5, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.